Ligand Pharmaceuticals (LGNYZ) Long-Term Deferred Tax (2016 - 2025)
Historic Long-Term Deferred Tax for Ligand Pharmaceuticals (LGNYZ) over the last 14 years, with Q3 2025 value amounting to $9.5 million.
- Ligand Pharmaceuticals' Long-Term Deferred Tax rose 1211282.05% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 1211282.05%. This contributed to the annual value of $72000.0 for FY2024, which is 6635.51% down from last year.
- Latest data reveals that Ligand Pharmaceuticals reported Long-Term Deferred Tax of $9.5 million as of Q3 2025, which was up 1211282.05% from $829000.0 recorded in Q2 2025.
- Ligand Pharmaceuticals' Long-Term Deferred Tax's 5-year high stood at $35.7 million during Q4 2021, with a 5-year trough of $72000.0 in Q4 2024.
- In the last 5 years, Ligand Pharmaceuticals' Long-Term Deferred Tax had a median value of $8.5 million in 2022 and averaged $14.6 million.
- Per our database at Business Quant, Ligand Pharmaceuticals' Long-Term Deferred Tax tumbled by 9908.56% in 2024 and then skyrocketed by 1211282.05% in 2025.
- Ligand Pharmaceuticals' Long-Term Deferred Tax (Quarter) stood at $35.7 million in 2021, then crashed by 76.13% to $8.5 million in 2022, then plummeted by 97.49% to $214000.0 in 2023, then tumbled by 66.36% to $72000.0 in 2024, then soared by 13130.56% to $9.5 million in 2025.
- Its Long-Term Deferred Tax was $9.5 million in Q3 2025, compared to $829000.0 in Q2 2025 and $546000.0 in Q1 2025.